I have to admit, I got in to a small position in this stock because of MWM, but after doing significant DD I increased my position to my comfort level. I don't have much experience investing in bio, so I am looking for some examples of how to think about a company moving from clinical to production, in terms of market cap, revenue, and longevity (buy-out?).
How do we look at this company medium and long term. Right now we are sitting on hopes of approval and authorizations for COVID and then the ongoing/upcoming studies for other uses in the pipeline. Prior to realizing this potential, the market will value hgen however it wants.
Once hgen starts moving product, is the sky the limit?
Market Data 
Markets 
AI
